Cytokinetics

Cardiovascular Account Specialist - U.S. Sales, Atlanta, GA

Remote

Not SpecifiedCompensation
Senior (5 to 8 years)Experience Level
Full TimeJob Type
UnknownVisa
Biotechnology, PharmaceuticalsIndustries

Position Overview

  • Location Type: Remote (Territory includes Marietta, GA and Lawrenceville, GA)
  • Employment Type: Full-time
  • Salary: (Salary information not provided in the text)

Cytokinetics is seeking a Cardiovascular Account Specialist to drive the launch of its first commercial product, a novel cardiac myosin inhibitor for Hypertrophic Cardiomyopathy (HCM), within a designated territory. This role requires a strategic and proactive individual to build relationships with key stakeholders and establish Cytokinetics as a trusted resource for HCM patients.

Requirements

  • Education: Bachelor’s Degree required.
  • Experience: 5+ years of experience in biotech/pharma sales.
  • Territory Ownership: Experience as a rep with sole ownership of the territory is highly preferred.
  • Preferred Experience:
    • Cardiology, rare disease, or specialty product experience.
    • Specialty product launch experience.

Responsibilities

  • Deliver sales results and operate autonomously within the assigned territory.
  • Serve as the single point of accountability for the successful launch of the product within the territory.
  • Develop territory-specific account plans to identify, assess, and prioritize opportunities.
  • Coordinate efforts with internal stakeholders including medical, payer, and patient navigation/support colleagues.
  • Become a subject matter expert and resource for customers, providing clinically relevant information about the product and disease.
  • Communicate approved resources (marketing materials, payer information, formulary coverage, patient support services, and educational programs) to healthcare professionals to create demand for the product launch.
  • Focus on benefiting HCM patients and their caregivers.

Application Instructions

  • (Application instructions not provided in the text)

Company Information

  • Company: Cytokinetics
  • Focus: A late-stage, specialty cardiovascular biopharmaceutical company focused on developing muscle activators and inhibitors for treating debilitating cardiovascular diseases.
  • Core Values:
    • Patients are our North Star: Dedicated to benefiting patients and caregivers.
    • Science is in our Soul: Committed to scientific excellence, integrity, and critical thinking.
    • We > Me: Strength lies in unity and diversity.
    • Make it Happen: Tenacity, resilience, and a forward-thinking mindset.

Skills

Biotech sales
Pharmaceutical sales
Cardiology
Rare disease
Specialty product launch
Territory planning
Account management
Cross-functional collaboration
Clinical product knowledge

Cytokinetics

Develops drugs for muscle function disorders

About Cytokinetics

Cytokinetics focuses on developing medicines that improve muscle function for patients with cardiovascular and neuromuscular diseases. Their products are small molecule drugs designed to either enhance or inhibit muscle function, tailored to specific therapeutic needs. The company has a pipeline of drugs, including omecamtiv mecarbil and reldesemtiv, which are in various stages of clinical trials. Unlike many competitors, Cytokinetics emphasizes rigorous scientific research and has conducted over 50 clinical trials to ensure the effectiveness of its treatments. The goal is to bring new therapies to market that address the unmet needs of patients suffering from conditions like heart failure, ALS, and HCM.

South San Francisco, CaliforniaHeadquarters
1998Year Founded
$58.4MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
501-1,000Employees

Risks

Increased competition could impact market share and profitability.
Potential delays in clinical trials could hinder drug commercialization.
Dependence on strategic partnerships may expose Cytokinetics to risks if challenges arise.

Differentiation

Cytokinetics focuses on muscle activators and inhibitors for cardiovascular and neuromuscular diseases.
The company has a robust pipeline including omecamtiv mecarbil and aficamten.
Cytokinetics engages in strategic partnerships, like with Sanofi, to expand market reach.

Upsides

Recent investments indicate strong interest in muscle activators and inhibitors.
Strategic partnerships, like with Sanofi, expand market reach and potential revenue.
Significant funding from Royalty Pharma supports commercial launch and R&D advancements.

Land your dream remote job 3x faster with AI